Cargando…

Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042–2050

Detalles Bibliográficos
Autores principales:	Tonneijck, Lennart, Smits, Mark M., Muskiet, Marcel H.A., Hoekstra, Trynke, Kramer, Mark H.H., Danser, A.H. Jan, ter Wee, Piet M., Diamant, Michaela, Joles, Jaap A., van Raalte, Daniel H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2019
Materias:	Errata
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385692/ https://www.ncbi.nlm.nih.gov/pubmed/30674545 http://dx.doi.org/10.2337/dc19-er03

Ejemplares similares

Biliary effects of liraglutide and sitagliptin, a 12‐week randomized placebo‐controlled trial in type 2 diabetes patients
por: Smits, Mark M., et al.
Publicado: (2016)

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
por: Smits, Mark M., et al.
Publicado: (2016)

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
por: Tonneijck, Lennart, et al.
Publicado: (2016)

The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes
por: Sivalingam, Suvanjaa, et al.
Publicado: (2021)

Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes
por: Smits, Mark M, et al.
Publicado: (2015)

Plasma uric acid and renal haemodynamics in type 2 diabetes patients
por: Suijk, Danii LS, et al.
Publicado: (2019)

Postprandial renal haemodynamic effects of the dipeptidyl peptidase‐4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double‐blind trial
por: Muskiet, Marcel H. A., et al.
Publicado: (2021)

Acute plasma amylase increase after glucagon‐like peptide ‐1 receptor agonist exenatide administration in Type 2 diabetes
por: Smits, M. M., et al.
Publicado: (2017)

Renal sinus fat and renal hemodynamics: a cross-sectional analysis
por: Spit, Karlinde A., et al.
Publicado: (2019)

Effects of dipeptidyl peptidase‐4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8‐week, randomized, controlled, double‐blind trial
por: Kraaijenhof, Jordan, et al.
Publicado: (2020)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahrén, Bo
Publicado: (2010)

Cost–benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2019)

Skin microvascular function and renal hemodynamics in overweight patients with type 2 diabetes: A cross‐sectional study
por: Bouman, Emma J., et al.
Publicado: (2021)

LHC MD 2042: Persistent Injection Oscillations
por: Karpov, Ivan, et al.
Publicado: (2018)

Erratum. Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE). A Randomized Controlled Trial. Diabetes Care 2016;39:455–464
por: Mita, Tomoya, et al.
Publicado: (2017)

Incretin Therapy for Type 2 Diabetes in Spain: A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin
por: Mezquita Raya, Pedro, et al.
Publicado: (2013)

Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140
por: Young-Hyman, Deborah, et al.
Publicado: (2017)

Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140
por: Young-Hyman, Deborah, et al.
Publicado: (2017)

The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
por: Ohki, Takamasa, et al.
Publicado: (2012)

Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684–1692
por: Inzucchi, Silvio E., et al.
Publicado: (2017)

Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes: A randomized, open-label trial
por: Pratley, Richard E., et al.
Publicado: (2012)

Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
por: Davies, M J, et al.
Publicado: (2012)

Real-World Clinical and Economic Outcomes of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Mellitus in the United States
por: Li, Qian, et al.
Publicado: (2014)

Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin
por: Pérez, Antonio, et al.
Publicado: (2015)

Erratum. George A. Bray, MD: Progress in Obesity—Multidisciplinary Research, Multidimensional Man. Diabetes Care 2016;39:1481–1485
por: Ryan, Donna H., et al.
Publicado: (2017)

Deciphering structure and topology of conserved COG2042 orphan proteins
por: Armengaud, Jean, et al.
Publicado: (2005)

Liraglutide Treatment in a Patient With HIV and Uncontrolled Insulin-Treated Type 2 Diabetes
por: Diamant, Michaela, et al.
Publicado: (2012)

Erratum. 2016 Presidential Address: Diabetes at 212°—Confronting the Invisible Disease. Diabetes Care 2016;39:1657–1663
por: Schatz, Desmond
Publicado: (2017)

Response to Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In Standards of Medical Care in Diabetes—2016. Diabetes Care 2016;39(Suppl. 1):S52–S59
por: Herman, William H., et al.
Publicado: (2016)

Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years
por: Li, Qian, et al.
Publicado: (2018)

Liraglutide and DPP-4 inhibitors – side effects comparative clinical study
por: TIMOFTE, LUMINIŢA, et al.
Publicado: (2013)

Liraglutide relieves cardiac dilated function than DPP‐4 inhibitors
por: Hiramatsu, Takeyuki, et al.
Publicado: (2018)

Response to Comment on Young-Hyman et al. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140
por: Young-Hyman, Deborah, et al.
Publicado: (2018)

Response to Comments on Young-Hyman et al. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140
por: Young-Hyman, Deborah, et al.
Publicado: (2017)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

DPP4 in Diabetes
por: Röhrborn, Diana, et al.
Publicado: (2015)

Diabetes Prevalence in Sweden at Present and Projections for Year 2050
por: Andersson, Tomas, et al.
Publicado: (2015)

Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus
por: Katsuno, Tomoyuki, et al.
Publicado: (2016)

Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece
por: Tzanetakos, Charalampos, et al.
Publicado: (2014)

Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis
por: Li, Mingxing, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_omh4jdndilcg90pn2981vaia66